These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21270232)

  • 21. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
    Sun W; Chen H; Liu Y; Zhao C; Nichols WW; Chen M; Zhang J; Ma Y; Wang H
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3642-9. PubMed ID: 19546358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.
    Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Faragon C; Malik M; Mendes RE; Jones RN; McNutt LA; Lodise TP
    BMC Infect Dis; 2017 Aug; 17(1):534. PubMed ID: 28764660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections.
    van Hal SJ; Jones M; Gosbell IB; Paterson DL
    PLoS One; 2011; 6(6):e21217. PubMed ID: 21713004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010.
    Edwards B; Milne K; Lawes T; Cook I; Robb A; Gould IM
    J Clin Microbiol; 2012 Feb; 50(2):318-25. PubMed ID: 22135252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
    Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
    J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
    Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
    J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns.
    van Hal SJ; Barbagiannakos T; Jones M; Wehrhahn MC; Mercer J; Chen D; Paterson DL; Gosbell IB
    J Antimicrob Chemother; 2011 Oct; 66(10):2284-7. PubMed ID: 21750101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus.
    Fitzgibbon MM; Rossney AS; O'Connell B
    J Clin Microbiol; 2007 Oct; 45(10):3263-9. PubMed ID: 17687008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
    Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nationwide surveillance of resistance rates of Staphylococcus aureus clinical isolates from Greek hospitals, 2012-2013.
    Souli M; Karaiskos I; Galani L; Maraki S; Perivolioti E; Argyropoulou A; Charissiadou A; Zachariadou L; Tsiplakou S; Papaioannou V; Tsorlini H; Katsifa H; Baka V; Pantazi P; Paschali A; Kyratsa A; Trikka-Graphakos E; Giannopoulou P; Vogiatzakis E; Moraitou H; Papadogeorgaki H; Avgerinou H; Panagea T; Pantazatou A; Petinaki E; Stamatopoulou G; Toutouza M; Karatzoglou I; Kontopoulou K; Orfanidou M; Karantani I; Fytas P; Tzanetou K; Platsouka E; Kazila P; Chli A; Statiri N; Giamarellou H
    Infect Dis (Lond); 2016 Apr; 48(4):287-292. PubMed ID: 26635179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.
    Yusof A; Engelhardt A; Karlsson A; Bylund L; Vidh P; Mills K; Wootton M; Walsh TR
    J Clin Microbiol; 2008 Sep; 46(9):3042-7. PubMed ID: 18596146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection.
    Takata T; Miyazaki M; Futo M; Hara S; Shiotsuka S; Kamimura H; Yoshimura H; Matsunaga A; Nishida T; Ishikura H; Ishikawa T; Tamura K; Tsuji BT
    Scand J Infect Dis; 2013 Mar; 45(3):203-12. PubMed ID: 23113753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials.
    Hos NJ; Jazmati N; Stefanik D; Hellmich M; AlSael H; Kern WV; Rieg S; Wisplinghoff H; Seifert H; Kaasch AJ
    J Infect; 2017 Mar; 74(3):248-259. PubMed ID: 28017826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of heteroresistant vancomycin intermediate Staphylococcus aureus among MRSA isolates.
    Gazel D; Erinmez M; Büyüktaş Manay A; Zer Y
    J Infect Dev Ctries; 2021 Jan; 15(1):89-94. PubMed ID: 33571150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.
    Castro BE; Berrio M; Vargas ML; Carvajal LP; Millan LV; Rios R; Hernandez AK; Rincon S; Cubides P; Forero E; Dinh A; Seas C; Munita JM; Arias CA; Reyes J; Diaz L
    J Antimicrob Chemother; 2020 Sep; 75(9):2424-2431. PubMed ID: 32562543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of heterogeneous vancomycin-intermediate
    Amberpet R; Sistla S; Sugumar M; Nagasundaram N; Manoharan M; Parija SC
    Indian J Med Res; 2019 Aug; 150(2):194-198. PubMed ID: 31670275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Precision of vancomycin and daptomycin MICs for methicillin-resistant Staphylococcus aureus and effect of subculture and storage.
    Charlton CL; Hindler JA; Turnidge J; Humphries RM
    J Clin Microbiol; 2014 Nov; 52(11):3898-905. PubMed ID: 25143569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.
    Horne KC; Howden BP; Grabsch EA; Graham M; Ward PB; Xie S; Mayall BC; Johnson PD; Grayson ML
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3447-52. PubMed ID: 19506056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreasing prevalence of isolates with vancomycin heteroresistance and vancomycin minimum inhibitory concentrations ≥2 mg/L in methicillin-resistant Staphylococcus aureus over 11 years: potential impact of vancomycin treatment guidelines.
    Khatib R; Sharma M; Johnson LB; Riederer K; Shemes S; Szpunar S
    Diagn Microbiol Infect Dis; 2015 Jul; 82(3):245-8. PubMed ID: 25935628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No evidence of vancomycin minimal inhibitory concentration creep or heteroresistance identified in pediatric Staphylococcus aureus blood isolates.
    Goldman JL; Harrison CJ; Myers AL; Jackson MA; Selvarangan R
    Pediatr Infect Dis J; 2014 Feb; 33(2):216-8. PubMed ID: 24413409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.